We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-14.95%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$1.72B
AUM Growth
-$950M
Cap. Flow
+$145M
Cap. Flow %
8.42%
Top 10 Hldgs %
48.56%
Holding
373
New
67
Increased
88
Reduced
111
Closed
78

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$59.4M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$32.9M
3
AMGN icon
Amgen
AMGN
+$18M
4
LLY icon
Eli Lilly
LLY
+$15.9M
5
BMY icon
Bristol-Myers Squibb
BMY
+$7.23M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$6.04M
2
ABT icon
Abbott
ABT
+$4.77M
3
RGNX icon
Regenxbio
RGNX
+$4.1M
4
CELG
Celgene Corp
CELG
+$3.94M
5
UTHR icon
United Therapeutics
UTHR
+$3.59M

Sector Composition

Rank Sector Weight
1 Miscellaneous 81.15%
2 Healthcare 18.37%
3 Financials 0.23%
4 Technology 0.2%
5 Consumer Staples 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RIBT
151
DELISTED
RiceBran Technologies
RIBT
$902K 0.05%
87,529
+8,085
+10% +$90.8K
RGNX icon
152
Regenxbio
RGNX
$525M
$898K 0.05%
48,400
-214,777
-82% -$4.1M
BPTH
153
DELISTED
Bio-Path Holdings Inc
BPTH
$896K 0.05%
166
-163
-50% -$790K
IOVA icon
154
PUT
Iovance Biotherapeutics
IOVA
$4.24B
$876K 0.05%
1,260
-6,641
-84% -$45.7K
CYTXW
155
DELISTED
Cytori Therapeutics Inc Warrant
CYTXW
$866K 0.05%
1,273,712
+378,695
+42% +$284K
PTN
156
Palatin Technologies
PTN
$19.5M
$853K 0.05%
+1,338
New +$931K
ADVM
157
DELISTED
Adverum Biotechnologies
ADVM
$822K 0.05%
28,331
-11,929
-30% -$390K
CHRS icon
158
Coherus Oncology
CHRS
$205M
$806K 0.05%
+28,618
New +$801K
VNDA icon
159
CALL
Vanda Pharmaceuticals
VNDA
$302M
$802K 0.05%
503
-744
-60% -$12K
VIRX
160
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$801K 0.05%
+6,324
New +$880K
DVAX
161
CALL
DELISTED
Dynavax Technologies
DVAX
$782K 0.05%
1,979
-8,005
-80% -$58.6K
TVTX icon
162
PUT
Travere Therapeutics
TVTX
$5.89B
$772K 0.04%
408
+7
+2% +$143
ATNM icon
163
Actinium Pharmaceuticals
ATNM
$39.3M
$760K 0.04%
28,954
-17,134
-37% -$536K
ACOR
164
CALL
DELISTED
Acorda Therapeutics
ACOR
$748K 0.04%
3
+2
+200% +$4.75K
HCA icon
165
PUT
HCA Healthcare
HCA
$91.8B
$740K 0.04%
100
-216
-68% -$16.2K
NSPRW
166
DELISTED
InspireMD, Inc. Warrants
NSPRW
$726K 0.04%
+1,210,106
New +$522K
ONSIZ
167
DELISTED
Oncobiologics, Inc. Series B Warrant
ONSIZ
$726K 0.04%
930,272
+3,621
+0.4% +$2.79K
GNMX
168
DELISTED
Aevi Genomic Medicine Inc
GNMX
$716K 0.04%
138,195
-3,782
-3% -$19.9K
XBI icon
169
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$693K 0.04%
+11,700
New +$722K
OCRX
170
DELISTED
Ocera Therapeutics, Inc.
OCRX
$690K 0.04%
328,632
-71,403
-18% -$167K
ENLV icon
171
Enlivex Ltd
ENLV
$15.4M
$687K 0.04%
1,100
-207
-16% -$175K
ARMP icon
172
Armata Pharmaceuticals
ARMP
$164M
$668K 0.04%
10,849
+7,125
+191% +$886K
VTGN icon
173
VistaGen Therapeutics
VTGN
$10.5M
$658K 0.04%
5,879
-5,758
-49% -$671K
ARCT icon
174
CALL
Arcturus Therapeutics
ARCT
$450M
$651K 0.04%
443
-246
-36% -$3.68K
PTCT icon
175
PUT
PTC Therapeutics
PTCT
$5.48B
$651K 0.04%
+597
New +$6.26K
5 6
7
8 9

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q4 2016 Portfolio in Review

As of Q4 2016, Sabby Management held 373 positions worth $1.72B, down 36% from $2.67B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Sabby Management deployed $145M of net new capital in Q4 2016, opening 67 new positions and adding to 88 existing holdings. Its largest new stake was Eli Lilly: 213,113 shares worth $15.7M.

By sector, the portfolio is most concentrated in Miscellaneous at 81% of assets, down from 90% a quarter earlier, followed by Healthcare and Financials.

On the sell side, the largest reduction was Regenxbio, an estimated $4.1M trimmed.

  • Sabby Management's largest Q4 2016 buy was Eli Lilly: 213,113 shares worth $15.7M.
  • Sabby Management added most to Sarepta Therapeutics in Q4 2016, an estimated $59.4M increase.
  • Sabby Management's biggest Q4 2016 reduction was Regenxbio, cutting an estimated $4.1M.
  • Sabby Management fully exited Shire pic in Q4 2016, selling an estimated $6.04M.
  • Sabby Management's ten largest holdings make up 49% of its $1.72B portfolio in Q4 2016.
  • Sabby Management opened 67 new positions and closed 78 in Q4 2016.
  • Sabby Management's portfolio value fell 36% quarter-over-quarter to $1.72B.

Based on Sabby Management's 13F filing for Q4 2016, filed 14 Feb 2017.